'Urgent target vessel revascularization' presentation slideshows

Updates on acute coronary syndrome

Updates on acute coronary syndrome. Dr. Eric Yeung Mar 2008. Acute coronary syndrome: The spectrum. Unstable angina (UA) Non-ST elevation myocardial infarction (NSTEMI) Closely related, different severity, myocardial injury ST-elevation myocardial infarction (STEMI). Case scenario. M/58.

1.45k views • 121 slides

STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients

STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients. Bruce Brodie, Adam Bensimhon, Nathan Fleishman, Charles Hansen, Mike Cooper, Henry Smith, John Edmunds, Jay Varanasi and Tom Stuckey LeBauer Cardiovascular Research Foundation Greensboro, NC TCT 2009

693 views • 31 slides

Factor IXa Inhibition Aptamer Technology Overview and First Results with RB006/RB007

Factor IXa Inhibition Aptamer Technology Overview and First Results with RB006/RB007. Mauricio G. Cohen, MD Associate Professor of Medicine Director, Cardiac Cath Lab. Disclosure Statement of Financial Interest.

615 views • 28 slides

492 views • 20 slides

Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT 2) Trial

ISAR-REACT 2 Trial. Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT 2) Trial. Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Adnan Kastrati. ISAR-REACT 2 Trial: Background.

295 views • 10 slides

ISAR-REACT 3

ISAR-REACT 3. Primary endpoint: death, MI, urgent target vessel revascularization, or in-hospital major bleeding was similar between the bivalirudin (8.3%) and UFH (8.7%) arms (p = 0.57) Bleeding significantly ? with bivalirudin compared with UFH: major (33%), minor (31%). (p = 0.57).

164 views • 1 slides